Candel Therapeutics, Inc. (NASDAQ: CADL), a pioneering entity in the biopharmaceutical landscape, is capturing investor attention with its impressive potential upside of 236.80%. This clinical-stage biotech company, headquartered in Needham, Massachusetts, is making significant strides in developing innovative cancer immunotherapies. With a current market capitalization of $303.59 million, Candel Therapeutics is positioning itself as a potentially lucrative investment in the healthcare sector.

The company’s pipeline includes promising candidates such as CAN-2409 and CAN-3110. CAN-2409, Candel’s lead product candidate, is undergoing Phase III trials for prostate cancer and Phase II trials for both pancreatic cancer and…